insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

MRKR · Marker Therapeutics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MRKR

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$2.84M-$2.35M$4.18M$3.14M-$3.47M$2.34M$2.58M-
SG&A$1.23M-$1.02M$945.2K$1.37M-$854.7K$1.14M$1.22M-
Total Operating Expenses$4.07M-$3.37M$5.12M$4.96M-$4.33M$3.48M$3.79M-
D&A----------
Operating Income($4.07M)-($2.14M)($4.26M)($4.61M)-($2.40M)($2.31M)($2.55M)-
Interest Expense----------
Income Tax----------
Net Income($3.18M)-($2.00M)($4.02M)($4.45M)-($2.31M)($2.19M)($2.39M)-
EPS - Basic($0.16)-($0.12)($0.29)($0.40)-($0.26)($0.25)($0.27)-
EPS - Diluted($0.16)-($0.12)($0.29)($0.40)-($0.26)($0.25)($0.27)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$14.92M$16.07M$17.59M$10.46M$13.69M$19.19M$9.00M$7.80M$11.32M$15.11M
Accounts Receivable----------
Inventory----------
Accounts Payable$1.50M$793.7K$951.0K$1.72M$1.30M$1.07M$1.90M$1.08M$1.20M$961.0K
Current Assets$17.43M$19.07M$21.73M$14.77M$16.99M$22.02M$10.91M$11.68M$14.09M$17.13M
Total Assets$17.43M$19.07M$21.73M$14.77M$16.99M$22.02M$10.91M$11.68M$14.09M$17.13M
Current Liabilities$3.64M$2.27M$3.35M$4.28M$2.50M$3.46M$3.46M$1.97M$2.30M$3.07M
Long-term Debt----------
Total Liabilities$3.64M$2.27M$3.35M$4.28M$2.50M$3.46M$3.46M$1.97M$2.30M$3.07M
Stockholders' Equity$13.80M$16.80M$18.39M$10.49M$14.49M$18.56M$7.45M$9.70M$11.79M$14.05M
Retained Earnings($462.36M)($459.18M)($457.48M)($455.48M)($451.46M)($447.02M)($443.18M)($440.87M)($438.68M)($436.29M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($1.40M)---($5.50M)---($3.84M)-
Investing Cash Flow----------
Financing Cash Flow----$505---$49.1K-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-18.2%--9.2%-27.2%-26.2%--21.2%-18.8%-17.0%-
Return on equity-23.0%--10.9%-38.3%-30.7%--31.0%-22.6%-20.3%-
Return on invested capital----------
Liquidity
Current ratio4.798.396.503.456.796.363.155.926.125.57
Quick ratio4.798.396.503.456.796.363.155.926.125.57
Cash ratio4.107.075.262.455.475.542.603.964.924.91
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.261.141.181.411.171.191.461.201.201.22
Liabilities / Assets0.210.120.150.290.150.160.320.170.160.18
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B1.8x-0.8x2.0x0.9x-3.4x5.0x3.2x-
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)11.6%-11.0%-84.6%-80.8%-25.0%44.2%49.5%-
Net income growth (YoY)28.5%-13.4%-83.1%-85.8%-22.6%-51.8%-
EPS growth (YoY)60.0%-53.8%-16.0%-48.1%-23.5%-52.6%-
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-4.8%-9.5%146.8%8.1%22.9%32.1%-55.4%-49.0%-25.9%-28.3%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Marker Therapeutics against the 5 most active filers in the same SIC group.